Table 5.
The reported trial results cited for comparison with the actual results.
| Clinical Trial | Treatment | ORR (%) | PFS (months) | OS (months) |
|---|---|---|---|---|
| Checkmate 067 | Nivolumab+Ipilimumab vs Nivolumab vs Ipilimumab | NA | NA | 72.1 vs 37.6 vs 19.9 |
| COMBI-d+COMBI-v | Dabrafenib+ Trametinib | 68% | 11.1 | 25.9 |
| ADMIRE | Dabrafenib + Trametinib or Vemurafenib + Cobimetinib | 57.4% | 9.2 | 22.6 |
| Anna C Pavlick et al | BRAF + MEK inhibitors vs Nivolumab + Ipilimumab | NA | 7.2 vs7.8 | 17.7 vs 48.4 |
| DREAMseq trial | Nivolumab + Ipilimumab vs Dabrafenib +Trametinib | 46% vs 43% | 11.8 vs 8.8 | NA |
| KEYNOTE-022 | Pembrolizumab + Dabrafenib and Trametinib vs placebo with Dabrafenib and Trametinib | 73% vs 67% | 17.0 vs 9.9 | 46.3 vs 26.3 |
| IMspire 150 trial | Atezolizumab, Vemurafenib, and Cobimetinib vs Atezolizumab placebo, Vemurafenib, and Cobimetinib | NA | 15.1 vs 10.6 | NA |
| BRAF mutated subgroup in this study | TT | 70% | 11.5 | 16.4 |
| IT | 43.8% | 19.2 | 33.4 |
ORR, objective response rate; PFS, progression-free survival; OS, overall survival; TT, targeted therapy; IT, immunotherapy; NA, Not Applicable.